Moderna invested heavily in manufacturing during the pandemic to meet high demand for its Covid vaccine. The company has been reducing capacity as demand for the shot falls. Last month ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the decline of its Covid business.

US scientists have discovered an alarming syndrome linked to the most commonly used Covid jab in the UK as the number of ...

Moderna's total revenue for the fourth quarter fell nearly 66% to $966 million, but beat analysts' expectations of $942.84 million. Most of those sales were generated by the COVID shot ...

US scientists have discovered an alarming syndrome linked to the most commonly used Covid jab in the UK as the number of ...

Regulatory authorities in the US are investigating a possible link between the new Pfizer/BioNTech bivalent COVID-19 booster ... or another bivalent shot from rival Moderna – also approved ...

At its update, Moderna highlighted its next-generation COVID-19 vaccine and respiratory syncytial virus (RSV) shot mRNA-1345, as well as a series of candidates for latent viruses, including ...

2025 Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares ...

In 2025, for instance, Moderna is expecting pivotal readouts for its seasonal flu, cytomegalovirus and norovirus vaccines, as well as a potential approval for its next-generation COVID-19 shot and an ...

The long-term risk for heart disease following a COVID infection was true for anyone, even for people who don't have any ...